NKG2 Inhibitors
Chemical inhibitors of NKG2 can selectively target pathways that are essential for the activation and function of natural killer (NK) cells within the immune system. Cyclosporin A and FK-506 (Tacrolimus) are inhibitors that target the calcineurin pathway, which is crucial for T-cell activation. While T-cells are different from NK cells, the reduced activation of T-cells indirectly leads to a decrease in the immune system's overall activity, including that of NK cells, thereby diminishing the functional capacity of NKG2. In a similar vein, Rapamycin (Sirolimus) forms a complex with FKBP12 that inhibits the mTOR pathway, which is integral to cell cycle progression and proliferation. The inhibition of mTOR is associated with a decrease in the activation threshold of NK cells, which in turn inhibits the functional activity of NKG2.
Further affecting the functionality of NKG2, chemical inhibitors like PD 98059 and U0126 block the MEK enzyme, leading to the suppression of the MAPK/ERK pathway. This pathway's inhibition can lead to a decrease in NK cell-mediated functions. Two other inhibitors, SB 203580 and SP600125, obstruct the p38 MAPK and JNK pathways, respectively, both of which are involved in the activation and function of immune cells, including NK cells. By inhibiting these pathways, SB 203580 and SP600125 reduce NK cell activity, thus functionally inhibiting NKG2. Additionally, PI3K inhibitors such as LY294002 and Wortmannin suppress signaling mechanisms that are pivotal for NK cell function, leading to a decrease in NKG2 activity. Src family kinases, which are essential in receptor signaling within NK cells, are targeted by PP2 and Dasatinib. These inhibitors prevent the activation of NK cells, thereby reducing the cytotoxic response associated with NKG2. Lastly, Imatinib, as a tyrosine kinase inhibitor, suppresses Abl kinase activity, which is also linked to the activation of NK cells, resulting in the functional inhibition of NKG2's capacity within the immune response.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A inhibits calcineurin, which is necessary for the activation of T-cells. NKG2 is an activating receptor found on NK cells, which are part of the innate immune system, and calcineurin inhibition can lead to reduced NK cell activity, therefore inhibiting NKG2. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $78.00 $151.00 | 9 | |
FK-506 binds to FKBP12, creating a complex that inhibits calcineurin, similar to Cyclosporin A. By inhibiting calcineurin, it suppresses T-cell activation, which can indirectly inhibit NKG2 by reducing overall immune activation including NK cell functions. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12, and the resulting complex inhibits mTOR, which is critical for cell cycle progression and proliferation. By inhibiting mTOR, this compound can indirectly inhibit the activation and function of NK cells, thus inhibiting NKG2. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective inhibitor of MEK, which blocks the MAPK/ERK pathway. This pathway is involved in the proliferation and activation of many immune cells, including NK cells, and its inhibition can lead to a decrease in NK cell-mediated functions, including those of NKG2. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor. The p38 MAPK pathway is involved in the production of inflammatory cytokines and the activation of immune cells. By inhibiting this pathway, SB 203580 can indirectly inhibit NKG2 by reducing NK cell activation and function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. PI3K is involved in cell growth, proliferation, and survival. By inhibiting PI3K, LY294002 can reduce the activation threshold and cytotoxic response of NK cells, thus functionally inhibiting NKG2. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, which can suppress the activation and function of NK cells by inhibiting PI3K signaling, leading to a functional inhibition of NKG2. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor. Src kinases are involved in receptor signaling in NK cells. By inhibiting Src kinases, PP2 can suppress NK cell activation, leading to functional inhibition of NKG2. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor that includes Src family kinases. It can inhibit the activation signal transduction in NK cells, leading to a decrease in NK cell cytotoxicity and thereby functionally inhibiting NKG2. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor, similar to PD 98059, and it prevents the activation of the MAPK/ERK pathway. This action can lead to suppressed NK cell function, thus inhibiting NKG2. | ||||||